FDA perspective: enrolment of elderly transplant recipients in clinical trials

Area of Science:

• Geriatric pharmacology
• Clinical trial design
• Transplantation medicine

Background:

• The U.S. Food and Drug Administration (FDA) has advocated for studying new drugs in elderly populations since 1989.
• Despite an aging population, older adults are consistently underrepresented in clinical trials, including those for transplantation.

Purpose of the Study:

• To summarize current FDA tools for encouraging and requiring the evaluation of safety and efficacy in elderly patients.
• To highlight the ongoing underrepresentation of elderly patients in clinical trials.
• To promote increased enrollment of older adults in transplantation clinical trials.

Main Methods:

• Review of FDA policies and guidance documents related to geriatric drug studies.
• Analysis of clinical trial enrollment trends concerning elderly populations.
• Summary of existing regulatory mechanisms to ensure data on older patients.

Main Results:

• The FDA has established mechanisms to encourage geriatric studies, but challenges in patient enrollment persist.
• Elderly patients remain a vulnerable and underrepresented demographic in critical therapeutic areas like transplantation.
• Current tools may not be sufficient to overcome barriers to elderly patient participation.

Conclusions:

• Collaboration between clinicians, sponsors, and investigators is crucial.
• Active efforts are needed to increase the participation of elderly patients in transplantation clinical trials.
• Ensuring representation of older adults in trials is vital for evaluating drug safety and efficacy in this demographic.